Whalesbook
FDC Limited has initiated a postal ballot process seeking shareholder approval to appoint Kishore Mukund Saletore as a Non-Executive Independent Director. His proposed tenure is for five years, from April 1, 2026, to March 31, 2031.
The company has set April 17, 2026, as the cut-off date for voting eligibility. Shareholders can cast their votes remotely via e-voting from April 28, 2026, until May 27, 2026. The results of the ballot are scheduled to be announced on or before May 29, 2026.
FDC Limited anticipates that Mr. Saletore's extensive financial expertise, honed through experience in global organizations, will significantly enhance the company's corporate governance framework. His insights are expected to provide valuable strategic direction, supporting the company's future growth and stability.
This appointment follows recent changes in FDC's leadership. Effective April 1, 2026, Managing Director Mohan Chandavarkar transitioned to the combined role of Chairman & Managing Director, succeeding CA Uday Kumar Gurkar upon the conclusion of his term as Independent Director and Chairman. FDC's board committees were also recently reconstituted.
Shareholders will vote on this key appointment, which signals a commitment to a long-term strategic vision and strengthened corporate governance. While the outcome is subject to investor participation and sentiment, a successful resolution reinforces FDC's governance initiatives.
FDC operates within the Indian pharmaceutical sector, a highly regulated industry. Its peers include major players like Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., Torrent Pharmaceuticals Ltd., and Lupin Ltd., all of whom also manage diverse stakeholder interests and governance considerations.